Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LV009 Injection in Recurrent/Refractory CD19 Positive Blood Tumors
NCT07330895Phase 1Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of LV009 in B cell acute lymphoblastic leukemia (B-ALL), lymphoma and hematologic and lymphoid malignancy (HLM), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Primary Outcome Measure at 2 years, Dose-Limiting Toxicities at 28 days and 1 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
LV009
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)lymphomahematologic and lymphoid malignancy (HLM)
Beyond the preview
Go deeper on NCT07330895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07330895.